(Q36093985)

English

Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

title

Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab (English)

1 reference

stated in

Europe PubMed Central

12 August 2017

1 reference

Sarita Dubey

1

1 reference

stated in

Europe PubMed Central

PubMed ID

15821248

retrieved

12 August 2017

Joan H Schiller

series ordinal

2

1 reference

stated in

Europe PubMed Central

12 August 2017

1 April 2005

1 reference

stated in

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

10

1 reference

stated in

Europe PubMed Central

12 August 2017

4

1 reference

stated in

Europe PubMed Central

12 August 2017

282-291

1 reference

stated in

Europe PubMed Central

PubMed ID

15821248

retrieved

12 August 2017

Identifiers

DOI

10.1634/THEONCOLOGIST.10-4-282

1 reference

stated in

Europe PubMed Central

12 August 2017

release_znxxelf63jbsjjttmzyvyo2m2m

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/znxxelf63jbsjjttmzyvyo2m2m

retrieved

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed ID

15821248

1 reference

stated in

Europe PubMed Central

PubMed ID

15821248

retrieved

12 August 2017

ResearchGate publication ID

7916020

0 references

(Q36093985)

Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)